Neck Pain, Whiplash Injuries
Conditions
Keywords
Whiplash,, injection,, lidocaine,, sham needling
Brief summary
To determine the efficacy of lidocaine injection of trigger points versus subcutaneous injection in patients with subacute whiplash associated disorder following injury.
Detailed description
This is a double-blind, randomized controlled trial to determine the efficacy of lidocaine injection of trigger points versus subcutaneous injection in patients with subacute whiplash associated disorder following injury. Outcomes include pain, objective assessment, self-report function recovery, impact on work performance and globe perceived effects which will be assessed 5 minutes, 2 and 6 weeks following injection.
Interventions
PROCEDURELidocaine
Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
OTHERSaline
The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
Sponsors
Hamilton Health Sciences Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* fulfill the Grade II Quebec Task Force classification of WAD, * with identifiable myofascial trigger points ( which occur with or without a taut band), * reproduction of recognizable pain with sustained pressure ( up to 10 seconds) on trigger points * aged 18 to 70 * a good understanding of informed consent and willing to attend this trial.
Exclusion criteria
* have serious injury such as fracture and internal bleeding * suspicion of upper cervical instability or neurological deficits * clinical evidence of radiculopathy * a history of active cancer, central nerve disorder, blood clotting disorders, needle phobia * anticoagulant medication user * previous experience with any type of needling for myofascial pain
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pain | 2 weeks following injection | 10 cm Visual Analog Scale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cervical range of motion | Immediately, 2 and 6 weeks after injection | — |
| self-report neck disability | Immediately, 2 and 6 weeks after injection | — |
| globe perceived effects | Immediately, 2 and 6 weeks after injection | The Short Form-12 |
| work performance | Immediately, 2 and 6 weeks after injection | questionnaire |
| pain | 5 minutes following injection | 10 cm Visual Analog Scale |
Countries
Canada
Outcome results
None listed